North America Leukapheresis Market Dynamics and Trends by 2028

The leukapheresis market in North America is expected to grow from US$ 28.54 million in 2021 to US$ 52.65 million by 2028; it is estimated to grow at a CAGR of 9.1% from 2021 to 2028.

Blood diseases disturb the overall well-being of patients. Anemia; hemophilia; von Willebrand disease (VWD); blood cancers such as myeloma, leukemia, and lymphoma are among the common blood diseases. The number of newly diagnosed leukemia cases increased from 354,500 in 1990 to 518,500 in 2017. In the US, the estimated number of people living with leukemia or are in remission from leukemia totals ~376,508. Leukemia was the sixth most common cause of cancer-related deaths in both men and women in the US during 2012–2016. In 2020, ~23,100 people are expected to die from leukemia (13,420 males and 9,680 females). Further, according to the National Heart, Lung, and Blood Institute, anemia affects more than 3 million Americans every year, while as per the WHO, it affects ~1.62 billion people worldwide. According to the Centers of Disease Control and Prevention (CDC), hemophilia A affects ~1 in 5,000 male births. The CDC survey for 2017 reported that Von Willebrand disease (VWD), one of the most commonly occurring bleeding disorders, affects up to 1% of the population. More than 14,600 men, women, and children were seen at hemophilia treatment centers for the treatment of VWD during 2012–2016. The rising incidence of these diseases maximizes the need for blood transfusion, thereby bolstering the demand for leukapheresis equipment. Two of the most common types of apheresis used for the removal of harmful substances from blood are cytapheresis and plasma exchange. Plasma exchange is used to treat disorders such as myasthenia gravis, thrombotic thrombocytopenic purpura, and multiple sclerosis. Cytapheresis, a process that removes the excess number of blood cells, is used in the treatment of leukemia, polycythemia, and thrombocythemia, among others.

North America has been witnessing a growing number of COVID-19 cases since its outbreak. The cases are also increasing in Mexico. In Mexico. At present, the majority of the diagnostic laboratories and research institutes are engaged in diagnosing the COVID-19 patients. Currently, the COVID-19 diagnostic testing industry is witnessing upsurge on account of a growing number of cases coupled with the increasing emergency use authorizations from the regulatory bodies. In addition, With the WHO declaring the COVID-19 outbreak a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups have stepped forward to develop treatments that target the infection. The U.S. Food and Drug Administration issued an emergency use authorization for a blood purification system to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure. The FDA issued this emergency use authorization to Terumo BCT Inc. and Marker Therapeutics AG for their Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge devices.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America leukapheresis market. The North America leukapheresis market is expected to grow at a good CAGR during the forecast period.

North America Leukapheresis Market Segmentation

 

North America Leukapheresis Market – By Product Type

• Leukapheresis Disposables
• Leukapheresis Devices

North America Leukapheresis Market – By Application

• Research Applications
• Therapeutic Applications

North America Leukapheresis Market – By Product Type

• Blood Component Providers and Blood Centers
• Hospitals and Transfusion Centers
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

North America Leukapheresis Market – By Country

• US
• Canada  
• Mexico     

North America Leukapheresis Market – Companies Mentioned

• Asahi Kasei Corporation                                 
• Fresenius SE & Co. KGaA                                
• Haemonetics Corporation                              
• Terumo Corporation                                        
• STEMCELL Technologies Inc.                          
• HemaCare  
• Macopharma
• AllCells
• STEMEXPRESS  
• BioIVT           

North America Leukapheresis Report Scope